Of additional interest was the observation that tumors from 60% of patients treated with adjuvant TMZ chemotherapy followed an alternative evolutionary path to high-grade glioma: these tumors showed hypermutation and harbored driver mutations in the RB and AKT-mTOR pathways that bore the signature of TMZ-induced mutagenesis. This evidence concerns the gene RB1 and glioma.